Area of research
Pulmonary and Respiratory Medicine · Political Science and International Relations
Research interest
Research interests include Lung Cancer Treatments and Mutations, Social Policy and Reform Studies, Parathyroid Disorders and Treatments, and PI3K/AKT/mTOR signaling in cancer.
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study